Testing of Homocysteine Metabolism-Related Conditions
Customize your policy alerts
Sign up for Healthfirst Policy PO-RE-082v3 alerts
Get alerted when Policy PO-RE-082v3 changes without checking for updates manually.
Monitor payer policy activity
Defines coverage and clinical guidance for screening, diagnosis, and monitoring of homocystinuria and related homocysteine metabolism disorders, including newborn screening, diagnostic biochemical testing, and genetic testing; applies to Healthfirst beneficiaries.
No material clinical or coverage changes in this revision.
Coverage Criteria for Testing of Homocysteine Metabolism-Related Conditions
Covered Indications
Covered when ANY of the following are met:
Enzymatic measurement of cystathionine beta-synthase (CBS) activity in cultured fibroblasts is not available in the USA and therefore is not an available diagnostic option for confirming CBS deficiency in practice.
The policy removed the pyridoxine (vitamin B6) challenge test from covered laboratory testing because it is a medical procedure rather than a laboratory assay and is therefore outside the scope of laboratory test management under this policy.
Genetic and Molecular Testing Indications
Molecular genetic analysis of CBS to confirm diagnosis of CBS deficiency and for carrier and prenatal testing when indicated.
E-HOD recommends molecular genetic analysis for confirmation; for prenatal diagnosis molecular analysis is preferred in the first trimester; enzyme analysis in cultured amniocytes may be used when family mutations are known (E-HOD).
Genotyping of MTHFR point mutations (eg, c.677C>T, c.1298A>C) in patients with suspected thrombophilia or part of evaluation for homocysteine-related disorders.
Several FDA-cleared in vitro diagnostic assays are available for MTHFR 677 and 1298 (e.g., Invader MTHFR 677/1298, eSensor MTHFR Genotyping Test, Verigene MTHFR Nucleic Acid Test).
Procedure Codes and Diagnostic Thresholds
Provider Actions, Documentation, and Billing Guidance
Benefit verification and coverage
Coverage of testing is subject to verification of the member's benefits at the time of the request. Newborn screening for homocysteine-related conditions (including screening for classic homocystinuria, homocystinuria in dried blood spots, and hypermethioninemia in dried blood spots) meets coverage criteria when consistent with the member's benefits. For individuals >18 years with suspected CBS-deficiency homocystinuria or for monitoring therapy in confirmed CBS deficiency, plasma total homocysteine (tHcy) testing meets coverage criteria when covered by the member's benefits.
- Newborn screening and specified plasma tHcy testing meet coverage criteria when consistent with member benefits.
- Reimbursement determinations depend on the evidence of coverage, applicable state and federal regulations, and provider participation agreement.
Prior Authorization
Prior authorization requirements are determined by the member's benefit plan and Healthfirst's administrative rules. This policy does not itself list an explicit universal prior authorization requirement, but providers must verify whether prior authorization is required under the member's specific plan before ordering testing. If prior authorization is required and not obtained, the claim may be denied.
- Check the member-specific benefits and Healthfirst prior authorization rules before ordering.
- Failure to obtain required prior authorization may result in claim denial.
Newborn screening follow-up algorithm
When an initial newborn screening methionine result exceeds the laboratory cut-off, follow-up should proceed step-wise: obtain a repeat dried blood spot submitted to the newborn screening program or perform a quantitative plasma amino acid analysis and plasma total homocysteine (tHcy) measurement. If high tHcy is confirmed, obtain plasma and urine samples for additional testing (methylmalonic acid, methionine, folate, and vitamin B12) before initiating treatment. Collect plasma tHcy specimens using recommended handling (centrifuge within an hour and keep refrigerated or frozen until analysis) when feasible.
- Step 1: Repeat dried blood spot to the newborn screening program OR quantitative plasma amino acids + plasma tHcy.
- Step 2: If tHcy is high, obtain plasma and urine for MMA, methionine, folate, and B12 prior to treatment.
- Specimen handling: centrifuge within 1 hour; keep at 4°C or frozen until analysis.
Step Therapy
No step therapy requirements are specified in this policy for laboratory testing related to homocysteine conditions. Providers must follow benefit-specific clinical management rules if any step edits are applied by the member's plan.
- No policy-specified step therapy requirements for these tests.
- If the member's plan applies step edits, follow the plan's requirements.
Benefit verification required
Providers must verify member benefits at the time of request; requests inconsistent with the member's evidence of coverage may be denied. Reimbursement and coverage determinations are based on the member's evidence of coverage, applicable state and federal requirements or mandates, and the provider's participation agreement.
- Benefit verification required at time of request — inconsistent requests may be denied.
- Reimbursement is determined by evidence of coverage, state/federal requirements, and provider agreement.
Documentation for Medical Necessity
Documentation to support medical necessity must be maintained in the medical record and submitted when requested. Acceptable documentation includes clinical indications, newborn screening results, repeat testing results, quantitative plasma amino acid analyses, plasma tHcy values, specimen collection/handling details, and any prior authorization or plan-coverage confirmations. Failure to follow coding, billing, and reimbursement guidelines (including proper documentation) could result in denial or recoupment of payment.
- Document clinical indication and diagnostic pathway (e.g., elevated newborn methionine → repeat DBS or plasma AA + tHcy).
- Retain and provide specimen handling information (centrifugation timing, temperature) for plasma tHcy.
- Include prior authorization or benefit verification records when applicable.
- Noncompliance with coding/billing/documentation may lead to denial or recoupment.
Eligibility Requirements
No top‑level eligibility logic is specified for this policy section.
No additional top‑level eligibility logic is specified for this policy section.
Services Not Covered
Measurement of CBS enzyme activity in cultured fibroblasts is not available in the USA and is therefore not a covered testing option for diagnosing homocystinuria due to CBS deficiency.
The pyridoxine (B6) challenge test has been removed from the list of covered laboratory tests because it is considered a medical procedure and is therefore outside the policy's laboratory test coverage.
Background and Clinical Context
Homocystinuria is an inherited disorder most often caused by pathogenic variants in the CBS gene resulting in impaired transsulfuration with accumulation of total homocysteine (tHcy) and methionine. Clinically, classic CBS deficiency presents with multisystem features including ocular (ectopia lentis), skeletal (marfanoid habitus), thrombotic events, and neurodevelopmental impairment. Plasma tHcy is the frontline diagnostic and monitoring analyte: normal is <15 µmol/L, neonates with homocystinuria typically measure >50 µmol/L, and untreated older individuals often have levels >100 µmol/L. Genetic testing of CBS (single‑gene or multigene panels including sequence and deletion/duplication analysis) is recommended to confirm diagnosis; historically, enzyme activity in cultured fibroblasts was a confirmatory option but is no longer available in the USA.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.